Supplementary Figure 1 from A Phase II Study of the Efficacy and Safety of the Combination Therapy of the MEK Inhibitor Refametinib (BAY 86-9766) Plus Sorafenib for Asian Patients with Unresectable Hepatocellular Carcinoma

MLA

Won Young Tak, et al. Supplementary Figure 1 from A Phase II Study of the Efficacy and Safety of the Combination Therapy of the MEK Inhibitor Refametinib (BAY 86-9766) Plus Sorafenib for Asian Patients with Unresectable Hepatocellular Carcinoma. Mar. 2023. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....180df5bebc37f2e679e0de974f8d88c2&authtype=sso&custid=ns315887.

APA

Won Young Tak, Chia-Jui Yen, Michael Jeffers, Heiko Krissel, Prabhu Rajagopalan, Christian Kappeler, Wen-Son Hsieh, Miah Hiang Tay, Joong-Won Park, Winnie Yeo, Ronnie T.P. Poon, Kun-Ming Rau, Chiun Hsu, Jung-Hwan Yoon, Cheng-Yao Lin, Hye Jin Choi, Jeong Heo, & Ho Yeong Lim. (2023). Supplementary Figure 1 from A Phase II Study of the Efficacy and Safety of the Combination Therapy of the MEK Inhibitor Refametinib (BAY 86-9766) Plus Sorafenib for Asian Patients with Unresectable Hepatocellular Carcinoma.

Chicago

Won Young Tak, Chia-Jui Yen, Michael Jeffers, Heiko Krissel, Prabhu Rajagopalan, Christian Kappeler, Wen-Son Hsieh, et al. 2023. “Supplementary Figure 1 from A Phase II Study of the Efficacy and Safety of the Combination Therapy of the MEK Inhibitor Refametinib (BAY 86-9766) Plus Sorafenib for Asian Patients with Unresectable Hepatocellular Carcinoma,” March. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....180df5bebc37f2e679e0de974f8d88c2&authtype=sso&custid=ns315887.